{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:40:31Z","timestamp":1775025631934,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1007\/s11908-003-0083-x","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T12:03:14Z","timestamp":1180094594000},"page":"266-276","source":"Crossref","is-referenced-by-count":34,"title":["Immune restoration inflammatory syndromes: The dark side of successful antiretroviral treatment"],"prefix":"10.1007","volume":"5","author":[{"given":"Matthias","family":"Stoll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhold E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"83_CR1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0171-2985(00)80065-0","volume":"202","author":"GM Behrens","year":"2000","unstructured":"Behrens GM, Meyer D, Stoll M, Schmidt RE: Immune reconstitution syndromes in human immuno-deficiency virus infection following effective antiretroviral therapy. Immunobiology 2000, 202:186\u2013193.","journal-title":"Immunobiology"},{"key":"83_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1468-1293.2000.00012.x","volume":"1","author":"MA French","year":"2000","unstructured":"French MA, Lenzo N, John M, et al.: Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000, 1:107\u2013115. Excellent overview of about 33 cases of immune restoration disease. The study was performed monocentric in Perth on 179 patients who stared HAART during a consecutive 10-month period. The reported cases with IRIS reflect a quarter of the 132 patients successfully treated with HAART. Therefore, this study characterizes a realistic spectrum of disease. Pathophysiologic aspects of these cases have been investigated and discussed by a group of immunologists and clinicians.","journal-title":"HIV Med"},{"key":"83_CR3","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1086\/313809","volume":"30","author":"VC Cheng","year":"2000","unstructured":"Cheng VC, Yuen KY, Chan WM, et al.: Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000, 30:882\u2013892. The outstanding merit of this review of more than hundred cases is the broad definition of immunorestoration disease, which may not be exclusively related to HIV infection and T-cell immunodeficiencies.","journal-title":"Clin Infect Dis"},{"key":"83_CR4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","volume":"360","author":"M Egger","year":"2002","unstructured":"Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119\u2013129. One of the most recent and best founded answers to the classic question in antiretroviral treatment: \u201cWhen to start?\u201d The study did not investigate immune restoration diseases but progression to AIDS or death in more than 12,000 patients after commencement of HAART. The high progression rate in patients with advanced immunodeficiency, especially in the first months after initiation of HAART, may reflect cases in which AIDSdefining disease had been unmasked by IRIS.","journal-title":"Lancet"},{"key":"83_CR5","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","volume":"352","author":"A Mocroft","year":"1998","unstructured":"Mocroft A, Vella S, Benfield TL, et al.: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725\u20131730.","journal-title":"Lancet"},{"key":"83_CR6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-200107270-00006","volume":"15","author":"JA Bartlett","year":"2001","unstructured":"Bartlett JA, DeMasi R, Quinn J, et al.: Overview of the effectiveness of triple combination therapy in antiretroviralnaive HIV-1 infected adults. AIDS 2001, 15:1369\u20131377. This classic meta-analysis of 23 HAART studies raised the question of whether HAART may be not hard enough for long-term success.","journal-title":"AIDS"},{"key":"83_CR7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1097\/00002030-200208160-00007","volume":"16","author":"J Palella","year":"2002","unstructured":"Palella J, Chmiel JS, Moorman AC, Holmberg SD: Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002, 16:1617\u20131626. In addition to the meta-analysis of Bartlett et al. [6\u2022], this large multicenter study shows that the success of HAART seems to be worse in usual clinical settings than in controlled clinical studies.","journal-title":"AIDS"},{"key":"83_CR8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/0003-4819-137-4-200208200-00008","volume":"137","author":"O Kirk","year":"2002","unstructured":"Kirk O, Reiss P, Uberti F, et al.: Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002, 137:239\u2013250.","journal-title":"Ann Intern Med"},{"key":"83_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2249.2001.01680.x","volume":"126","author":"A Scott","year":"2001","unstructured":"Scott A, Aboulker JP, Durier C, et al.: CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART. Clin Exp Immunol 2001, 126:295\u2013303.","journal-title":"Clin Exp Immunol"},{"key":"83_CR10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/00002030-200205030-00017","volume":"16","author":"V Grosse","year":"2002","unstructured":"Grosse V, Schulte A, Weber K, et al.: Normalization of cytomegalovirus-specific CD4 T cells in HIV-1-infected individuals receiving antiretroviral therapy. AIDS 2002, 16:1075\u20131077.","journal-title":"AIDS"},{"key":"83_CR11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00126334-200204150-00001","volume":"29","author":"M Plana","year":"2002","unstructured":"Plana M, Martinez C, Garcia F, et al.: Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. J Acquir Immune Defic Syndr 2002, 29:429\u2013434.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"83_CR12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00126334-200112010-00003","volume":"28","author":"G Gerna","year":"2001","unstructured":"Gerna G, Piccinini G, Genini E, et al.: Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART. J Acquir Immune Defic Syndr 2001, 28:320\u2013331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"83_CR13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/clim.2001.5164","volume":"102","author":"CG Lange","year":"2002","unstructured":"Lange CG, Valdez H, Medvik K, et al.: CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002, 102:154\u2013161.","journal-title":"Clin Immunol"},{"key":"83_CR14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1089\/088922202760265632","volume":"18","author":"RL Hengel","year":"2002","unstructured":"Hengel RL, Allende MC, Dewar RL, et al.: Increasing CD4+ T cells specific for tuberculosis correlate with improved clinical immunity after highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2002, 18:969\u2013975.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"83_CR15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/088922201300343681","volume":"17","author":"DW Notermans","year":"2001","unstructured":"Notermans DW, de J, Goudsmit J, et al.: Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses 2001, 17:1003\u20131008.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"83_CR16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0171-2985(00)80063-7","volume":"202","author":"K Weber","year":"2000","unstructured":"Weber K, Meyer D, Grosse V, et al.: Reconstitution of NK cell activity in HIV-1 infected individuals receiving antiretroviral therapy. Immunobiology 2000, 202:172\u2013178.","journal-title":"Immunobiology"},{"key":"83_CR17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/25374","volume":"396","author":"DC Douek","year":"1998","unstructured":"Douek DC, McFarland RD, Keiser PH, et al.: Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690\u2013695.","journal-title":"Nature"},{"key":"83_CR18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/00002030-200109280-00002","volume":"15","author":"L Teixeira","year":"2001","unstructured":"Teixeira L, Valdez H, McCune JM, et al.: Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001, 15:1749\u20131756.","journal-title":"AIDS"},{"key":"83_CR19","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/00002030-200109280-00003","volume":"15","author":"CM Steffens","year":"2001","unstructured":"Steffens CM, Smith KY, Landay A, et al.: T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals. AIDS 2001, 15:1757\u20131764.","journal-title":"AIDS"},{"key":"83_CR20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/00002030-200208160-00006","volume":"16","author":"C Mussini","year":"2002","unstructured":"Mussini C, Pinti M, Borghi V, et al.: Features of \u2018CD4-exploders\u2019, HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS 2002, 16:1609\u20131616.","journal-title":"AIDS"},{"key":"83_CR21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00002030-200202150-00007","volume":"16","author":"GR Kaufmann","year":"2002","unstructured":"Kaufmann GR, Bloch M, Finlayson R, et al.: The extent of HIV-1-related immunodeficiency and age predict the longterm CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002, 16:359\u2013367.","journal-title":"AIDS"},{"key":"83_CR22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/JVI.75.1.234-241.2001","volume":"75","author":"G Carcelain","year":"2001","unstructured":"Carcelain G, Tubiana R, Samri A, et al.: Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001, 75:234\u2013241. Immunologic study that refutes the \u201cautovaccination hypothesis\u201d in HIV infection.","journal-title":"J Virol"},{"key":"83_CR23","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/00002030-199814000-00013","volume":"12","author":"C Michelet","year":"1998","unstructured":"Michelet C, Arvieux C, Francois C, et al.: Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998, 12:1815\u20131822.","journal-title":"AIDS"},{"key":"83_CR24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/ajrccm.158.1.9712001","volume":"158","author":"M Narita","year":"1998","unstructured":"Narita M, Ashkin D, Hollender ES, Pitchenik AE: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998, 158:157\u2013161.","journal-title":"Am J Respir Crit Care Med"},{"key":"83_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00002030-199902040-00005","volume":"13","author":"NA Foudraine","year":"1999","unstructured":"Foudraine NA, Hovenkamp E, Notermans DW, et al.: Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13:177\u2013184.","journal-title":"AIDS"},{"key":"83_CR26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0140-6736(97)04352-3","volume":"351","author":"EM Race","year":"1998","unstructured":"Race EM, Adelson-Mitty J, Kriegel GR, et al.: Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998, 351:252\u2013255.","journal-title":"Lancet"},{"key":"83_CR27","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1164\/ajrccm.159.6.9807152","volume":"159","author":"JM Naccache","year":"1999","unstructured":"Naccache JM, Antoine M, Wislez M, et al.: Sarcoid-like pulmonary disorder in human immunodeficiency virusinfected patients receiving antiretroviral therapy. Am J Respir Crit Care Med 1999, 159:2009\u20132013.","journal-title":"Am J Respir Crit Care Med"},{"key":"83_CR28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1086\/314528","volume":"178","author":"RS Wallis","year":"1998","unstructured":"Wallis RS, Johnson JL, Okwera A, et al.: Pentoxifylline in human immunodeficiency virus-positive tuberculosis: safety at 4 years. J Infect Dis 1998, 178:1861\u20131864.","journal-title":"J Infect Dis"},{"key":"83_CR29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/aid.1998.14.299","volume":"14","author":"R Heijligenberg","year":"1998","unstructured":"Heijligenberg R, Romijn JA, Ackermans M, et al.: The maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit lipopolysaccharide-stimulated tumor necrosis factor alpha production. AIDS Res Hum Retroviruses 1998, 14:299\u2013303.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"83_CR30","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1001\/archinte.158.16.1828","volume":"158","author":"MS Dworkin","year":"1998","unstructured":"Dworkin MS, Fratkin MD: Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS. Arch Intern Med 1998, 158:1828.","journal-title":"Arch Intern Med"},{"key":"83_CR31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1086\/313705","volume":"30","author":"SK Cinti","year":"2000","unstructured":"Cinti SK, Kaul DR, Sax PE, et al.: Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis 2000, 30:511\u2013514.","journal-title":"Clin Infect Dis"},{"key":"83_CR32","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/344892","volume":"186","author":"SF Stone","year":"2002","unstructured":"Stone SF, Lee S, Keane NM, et al.: Association of Increased Hepatitis C Virus (HCV)-Specific IgG and Soluble cd26 dipeptidyl peptidase iv enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-hcv-coinfected patients. J Infect Dis 2002, 186:1498\u20131502.","journal-title":"J Infect Dis"},{"key":"83_CR33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)00437-4","volume":"108","author":"LA Proia","year":"2000","unstructured":"Proia LA, Ngui SL, Kaur S, et al.: Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy. Am J Med 2000, 108:249\u2013251.","journal-title":"Am J Med"},{"key":"83_CR34","first-page":"829","volume":"12","author":"JK Rockstroh","year":"1998","unstructured":"Rockstroh JK, Theisen A, Kaiser R, et al.: Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs. AIDS 1998, 12:829\u2013830.","journal-title":"AIDS"},{"key":"83_CR35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00126334-200104010-00008","volume":"26","author":"M Bonacini","year":"2001","unstructured":"Bonacini M, Lin HJ, Hollinger FB: Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001, 26:340\u2013344.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"83_CR36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/00002030-200006160-00013","volume":"14","author":"JR Deayton","year":"2000","unstructured":"Deayton JR, Wilson P, Sabin CA, et al.: Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000, 14:1163\u20131170.","journal-title":"AIDS"},{"key":"83_CR37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/jama.283.5.653","volume":"283","author":"SM Whitcup","year":"2000","unstructured":"Whitcup SM: Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA 2000, 283:653\u2013657.","journal-title":"JAMA"},{"key":"83_CR38","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/340636","volume":"185","author":"SF Stone","year":"2002","unstructured":"Stone SF, Price P, Tay K, French MA: Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMVspecific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002, 185:1813\u20131817. Proof of the concept that certain clinical features of immune restoration inflammatory disease are associated with an imbalance in Th1\/ Th2 immune responses.","journal-title":"J Infect Dis"},{"key":"83_CR39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00126334-199911010-00003","volume":"22","author":"M Labetoulle","year":"1999","unstructured":"Labetoulle M, Goujard C, Frau E, et al.: Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years. J Acquir Immune Defic Syndr 1999, 22:228\u2013234.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"83_CR40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(01)00703-3","volume":"110","author":"P Domingo","year":"2001","unstructured":"Domingo P, Torres OH, Ris J, Vazquez G: Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001, 110:605\u2013609.","journal-title":"Am J Med"},{"key":"83_CR41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1468-1293.1999.00003.x","volume":"1","author":"PA Fox","year":"1999","unstructured":"Fox PA, Barton SE, Francis N, et al.: Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med 1999, 1:10\u201318.","journal-title":"HIV Med"},{"key":"83_CR42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002030-200201040-00009","volume":"16","author":"E Righetti","year":"2002","unstructured":"Righetti E, Ballon G, Ometto L, et al.: Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 2002, 16:63\u201373. This study gives direct evidence that predominance of Th2 immune response may increase the burden of virus in certain coinfections. In this way, IRIS may be caused not only by the augmentation of inflammatory response, but also as a trigger of an underlying disease.","journal-title":"AIDS"},{"issue":"Suppl 1","key":"83_CR43","first-page":"S27","volume":"21","author":"AE Grulich","year":"1999","unstructured":"Grulich AE: AIDS-associated non-Hodgkin\u2019s lymphoma in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 1999, 21 Suppl 1:S27-S30.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"83_CR44","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJM199906173402415","volume":"340","author":"C Zietz","year":"1999","unstructured":"Zietz C, Bogner JR, Goebel FD, Lohrs U: An unusual cluster of cases of Castleman\u2019s disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999, 340:1923\u20131924.","journal-title":"N Engl J Med"},{"key":"83_CR45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1464-2662.2001.00096.x","volume":"3","author":"SF Stone","year":"2002","unstructured":"Stone SF, Price P, Keane NM, et al.: Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002, 3:21\u201327.","journal-title":"HIV Med"},{"key":"83_CR46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/13550280152537247","volume":"7","author":"P Cinque","year":"2001","unstructured":"Cinque P, Pierotti C, Vigano MG, et al.: The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001, 7:358\u2013363.","journal-title":"J Neurovirol"},{"key":"83_CR47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/00002030-200205030-00008","volume":"16","author":"TD Langford","year":"2002","unstructured":"Langford TD, Letendre SL, Marcotte TD, et al.: Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002, 16:1019\u20131029.","journal-title":"AIDS"},{"key":"83_CR48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/PL00011252","volume":"20","author":"R Murray","year":"2001","unstructured":"Murray R, Mallal S, Heath C, French M: Cerebral mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001, 20:199\u2013201.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"83_CR49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/jinf.2001.0917","volume":"44","author":"P Makela","year":"2002","unstructured":"Makela P, Howe L, Glover S, et al.: Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV. J Infect 2002, 44:47\u201349.","journal-title":"J Infect"},{"key":"83_CR50","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(05)79022-X","volume":"351","author":"G Behrens","year":"1998","unstructured":"Behrens G, Knuth C, Schedel I, et al.: Highly active antiretroviral therapy. Lancet 1998, 351:1057\u20131058.","journal-title":"Lancet"},{"key":"83_CR51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1258\/095646202760159747","volume":"13","author":"C Bell","year":"2002","unstructured":"Bell C, Nelson M, Kaye S: A case of immune reconstitution rheumatoid arthritis. Int J STD AIDS 2002, 13:580\u2013581.","journal-title":"Int J STD AIDS"},{"key":"83_CR52","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0002-9343(00)00562-3","volume":"109","author":"P Sellier","year":"2000","unstructured":"Sellier P, Monsuez JJ, Evans J, et al.: Human immunodeficiency virus-associated polymyositis during immune restoration with combination antiretroviral therapy. Am J Med 2000, 109:510\u2013512.","journal-title":"Am J Med"},{"key":"83_CR53","first-page":"4254","volume":"85","author":"V Jubault","year":"2000","unstructured":"Jubault V, Penfornis A, Schillo F, et al.: Sequential occurrence of thyroid autoantibodies and Graves\u2019 disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 2000, 85:4254\u20134257.","journal-title":"J Clin Endocrinol Metab"},{"key":"83_CR54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00002030-200101050-00026","volume":"15","author":"I Sereti","year":"2001","unstructured":"Sereti I, Sarlis NJ, Arioglu E, et al.: Alopecia universalis and Graves\u2019 disease in the setting of immune restoration after highly active antiretroviral therapy. AIDS 2001, 15:138\u2013140.","journal-title":"AIDS"},{"key":"83_CR55","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2214\/ajr.177.6.1771427","volume":"177","author":"C Wittram","year":"2001","unstructured":"Wittram C, Fogg J, Farber H: Immune restoration syndrome manifested by pulmonary sarcoidosis. AJR Am J Roentgenol 2001, 177:1427.","journal-title":"AJR Am J Roentgenol"},{"key":"83_CR56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1468-1293.2002.00115.x","volume":"3","author":"SM Barry","year":"2002","unstructured":"Barry SM, Lipman MC, Deery AR, et al.: Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002, 3:207\u2013211.","journal-title":"HIV Med"},{"key":"83_CR57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/341974","volume":"35","author":"CE Koval","year":"2002","unstructured":"Koval CE, Gigliotti F, Nevins D, Demeter LM: Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002, 35:491\u2013493.","journal-title":"Clin Infect Dis"},{"key":"83_CR58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/jinf.2002.1052","volume":"45","author":"M Trevenzoli","year":"2002","unstructured":"Trevenzoli M, Cattelan AM, Rea F, et al.: Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era. J Infect 2002, 45:173.","journal-title":"J Infect"},{"key":"83_CR59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1442-9071.2001.00443.x","volume":"29","author":"AD Gajdatsy","year":"2001","unstructured":"Gajdatsy AD, Tay K: Microsporidial eratoconjunctivitis after HAART. Clin Experiment Ophthalmol 2001, 29:327\u2013329.","journal-title":"Clin Experiment Ophthalmol"},{"key":"83_CR60","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/338637","volume":"34","author":"MD King","year":"2002","unstructured":"King MD, Reznik DA, Daniels CM, et al.: Human papillomavirusassociated oral warts among human immunodeficiency virusseropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002, 34:641\u2013648.","journal-title":"Clin Infect Dis"},{"key":"83_CR61","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/00002030-200207050-00018","volume":"16","author":"JF Abino","year":"2002","unstructured":"Abino JF, Peraldi R, Lepidi H, et al.: Bacillary splenitis during immune restoration in an HIV-infected patient. AIDS 2002, 16:1429\u20131430.","journal-title":"AIDS"},{"key":"83_CR62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1086\/321826","volume":"33","author":"DJ Skiest","year":"2001","unstructured":"Skiest DJ: Osteonecrosis in human immunodeficiency virus-infected patients may not be related to immune reconstitution. Clin Infect Dis 2001, 33:268\u2013270.","journal-title":"Clin Infect Dis"},{"key":"83_CR63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1258\/0956462021924514","volume":"13","author":"NA Qazi","year":"2002","unstructured":"Qazi NA, Morlese JF, King DM, et al.: True gynaecomastia, another manifestation of immune reconstitution disease? Int J STD AIDS 2002, 13:59\u201365.","journal-title":"Int J STD AIDS"},{"key":"83_CR64","first-page":"669","volume":"137","author":"JF Silvestre","year":"2001","unstructured":"Silvestre JF, Albares MP, Ramon R, Botella R: Cutaneous intolerance to tattoos in a patient with human immunodeficiency virus: a manifestation of the immune restoration syndrome. Arch Dermatol 2001, 137:669\u2013670.","journal-title":"Arch Dermatol"},{"key":"83_CR65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00002018-200023010-00004","volume":"23","author":"G Behrens","year":"2000","unstructured":"Behrens G, Stoll M, Schmidt RE: Lipodystrophy syndrome with protease inhibitors: what is it, what causes it and how can it be managed ? Drug Saf 2000, 23:57\u201376.","journal-title":"Drug Saf"},{"key":"83_CR66","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1097\/00002030-200109280-00029","volume":"15","author":"C Grahame","year":"2001","unstructured":"Grahame C, Alber DG, Lucas SB, et al.: Association between Kaposi\u2019s sarcoma and atherosclerosis: implications for gammaherpesviruses and vascular disease. AIDS 2001, 15:1902\u20131904.","journal-title":"AIDS"},{"key":"83_CR67","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1006\/jmcc.2000.1271","volume":"32","author":"W Lewis","year":"2000","unstructured":"Lewis W: Atherosclerosis in AIDS: potential pathogenetic roles of antiretroviral therapy and HIV. J Mol Cell Cardiol 2000, 32:2115\u20132129.","journal-title":"J Mol Cell Cardiol"},{"key":"83_CR68","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1086\/319219","volume":"32","author":"SC Johnson","year":"2001","unstructured":"Johnson SC, Benson CA, Johnson DW, Weinberg A: Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis 2001, 32:815\u2013819.","journal-title":"Clin Infect Dis"},{"key":"83_CR69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1386-6532(01)00200-1","volume":"22","author":"P Price","year":"2001","unstructured":"Price P, Mathiot N, Krueger R, et al.: Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol 2001, 22:279\u2013287.","journal-title":"J Clin Virol"},{"key":"83_CR70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2249.2001.01647.x","volume":"126","author":"NM Keane","year":"2001","unstructured":"Keane NM, Price P, Lee S, et al.: An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001, 126:111\u2013116.","journal-title":"Clin Exp Immunol"},{"key":"83_CR71","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00126334-200010010-00009","volume":"25","author":"H Behbahani","year":"2000","unstructured":"71. Behbahani H, Landay A, Patterson BK, et al.: Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000, 25:150\u2013156.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"83_CR72","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/00002030-200210180-00009","volume":"16","author":"P Price","year":"2002","unstructured":"Price P, Morahan G, Huang D, et al.: Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002, 16:2043\u20132047. In addition to previously described associations of IRIS to certain histocompatibility antigens, this study demonstrates that polymorphisms of genetic factors have an impact on the manifestation of IRIS.","journal-title":"AIDS"},{"key":"83_CR73","first-page":"37","volume":"8","author":"JR Deayton","year":"2001","unstructured":"Deayton JR: Changing trends in cytomegalovirus disease in HIV-infected patients. Herpes 2001, 8:37\u201340.","journal-title":"Herpes"},{"key":"83_CR74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5694\/j.1326-5377.1998.tb123372.x","volume":"169","author":"M John","year":"1998","unstructured":"John M, French MA: Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998, 169:473\u2013474.","journal-title":"Med J Aust"},{"key":"83_CR75","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archderm.135.9.1129","volume":"135","author":"G Del","year":"1999","unstructured":"Del G, Durant J, Counillon E, et al.: Mycobacterial cutaneous manifestations: a new sign of immune restoration syndrome in patients with acquired immunodeficiency syndrome. Arch Dermatol 1999, 135:1129\u20131130.","journal-title":"Arch Dermatol"},{"key":"83_CR76","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1086\/340714","volume":"35","author":"JA Aberg","year":"2002","unstructured":"Aberg JA, Chin H, McCutchan A, et al.: Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy. Clin Infect Dis 2002, 35:E8-E13.","journal-title":"Clin Infect Dis"},{"key":"83_CR77","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0140-6736(96)11431-8","volume":"349","author":"MA Jacobson","year":"1997","unstructured":"Jacobson MA, Zegans M, Pavan PR, et al.: Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997, 349:1443\u20131445.","journal-title":"Lancet"},{"key":"83_CR78","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0002-9394(99)80134-2","volume":"125","author":"ME Zegans","year":"1998","unstructured":"Zegans ME, Walton RC, Holland GN, et al.: Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998, 125:292\u2013300.","journal-title":"Am J Ophthalmol"},{"key":"83_CR79","first-page":"452","volume":"12","author":"NA Qazi","year":"2002","unstructured":"Qazi NA, Morlese JF, Walsh JC, et al.: Case report. Severe cutaneous ulceration secondary to cytomegalovirus inclusion disease during successful immune reconstitution with HAART. AIDS Read 2002, 12:452\u2013457.","journal-title":"AIDS Read"},{"key":"83_CR80","unstructured":"Forest DM, Phillips P, Melosky B, et al.: Several visceral Kaposi\u2019s sarcoma due to immune reconstitution associatd with reduction in plasma viral load without increase in CD4+ count. In XIV International AIDS Conference. Barcelona; 2002:Abstract ThPeB7187."},{"key":"83_CR81","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/00002030-199817000-00010","volume":"12","author":"M John","year":"1998","unstructured":"John M, Flexman J, French MA: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998, 12:2289\u20132293.","journal-title":"AIDS"},{"key":"83_CR82","first-page":"608","volume":"11","author":"PE Tsambiras","year":"2001","unstructured":"Tsambiras PE, Larkin JA, Houston SH: Case report. Toxoplasma encephalitis after initiation of HAART. AIDS Read 2001, 11:608\u2013616.","journal-title":"AIDS Read"},{"key":"83_CR83","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1164\/ajrccm.165.12.165121","volume":"165","author":"GL Dean","year":"2002","unstructured":"Dean GL, Williams DI, Churchill DR, Fisher MJ: Transient clinical deterioration in HIV patients with Pneumocystis carinii pneumonia after starting highly active antiretroviral therapy: another case of immune restoration inflammatory syndrome. Am J Respir Crit Care Med 2002, 165:1670.","journal-title":"Am J Respir Crit Care Med"},{"key":"83_CR84","first-page":"451","volume":"3","author":"J Gilad","year":"2001","unstructured":"Gilad J, Borer A, Hallel H, et al.: Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Isr Med Assoc J 2001, 3:451\u2013452.","journal-title":"Isr Med Assoc J"},{"key":"83_CR85","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/318708","volume":"32","author":"L De","year":"2001","unstructured":"De L, Pineda JA, Delgado J, et al.: Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001, 32:633\u2013635.","journal-title":"Clin Infect Dis"},{"key":"83_CR86","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1086\/344325","volume":"186","author":"G Del","year":"2002","unstructured":"Del G, Mary K, Pradier C, et al.: Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002, 186:1366\u20131370.","journal-title":"J Infect Dis"},{"key":"83_CR87","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1468-3083.2001.00337.x","volume":"15","author":"S Handa","year":"2001","unstructured":"Handa S, Bingham JS: Dermatological immune restoration syndrome: does it exist? J Eur Acad Dermatol Venereol 2001, 15:430\u2013432.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"83_CR88","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1468-1293.2000.00037.x","volume":"1","author":"T Aldeen","year":"2000","unstructured":"Aldeen T, Horgan M, Macallan DC, et al.: Is acute appendicitis another inflammatory condition associated with highly active antiretroviral therapy (HAART)? HIV Med 2000, 1:252\u2013255.","journal-title":"HIV Med"},{"key":"83_CR89","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1067\/mjd.2002.119105","volume":"46","author":"HA Ward","year":"2002","unstructured":"Ward HA, Russo GG, Shrum J: Cutaneous manifestations of antiretroviral therapy. J Am Acad Dermatol 2002, 46:284\u2013293.","journal-title":"J Am Acad Dermatol"},{"key":"83_CR90","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/317503","volume":"31","author":"P Monier","year":"2000","unstructured":"Monier P, McKown K, Bronze MS: Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus. Clin Infect Dis 2000, 31:1488\u20131492.","journal-title":"Clin Infect Dis"},{"key":"83_CR91","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1378\/chest.119.3.978","volume":"119","author":"R Lenner","year":"2001","unstructured":"Lenner R, Bregman Z, Teirstein AS, DePalo L: Recurrent pulmonary sarcoidosis in HIV-infected patients receiving highly active antiretroviral therapy. Chest 2001, 119:978\u2013981.","journal-title":"Chest"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-003-0083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-003-0083-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-003-0083-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:21:58Z","timestamp":1559434918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-003-0083-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s11908-003-0083-x","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}